The abstract is read at the publisher; the summary is JClub's.
NMU-expressing IGHV1-69+ IgG4+ plasma cells were identified as a previously unrecognized pathogenic subset linked to IgG4-related disease recurrence during rituximab-treated longitudinal follow-up.
- Why it matters: IgG4-RD involves IgG4+ plasma cell tissue infiltration, but the specific B-cell–driven subsets and relapse biomarkers during B-cell depletion remain unclear.
- What they did: Using longitudinal multiomics on 119 peripheral blood samples from rituximab-treated IgG4-RD patients across active, remission, and relapse phases, the study integrated single-cell transcriptomics, BCR sequencing, and serum proteomics with matched tissue from submandibular gland and lymph nodes, plus Sjögren’s syndrome and healthy controls.
- The result: After B-cell depletion, reconstitution dynamics of pathogenic plasma cells and concurrent shifts in CD4+ Tfh and IL10+ dnT mirrored remission and relapse, alongside reduced proinflammatory immune profiles, enabling biomarker-based monitoring and relapse prediction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.